Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study

Bhole, Vidula; Choi, Jee Woong; Kim, Sung Woo; Vera, Mary A. De; Choi, Hyon K.

doi:10.1016/j.amjmed.2010.03.027

Cited by 257 publications

(188 citation statements)

References 28 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…Although several studies showed that BMI, hypertension, and uric acid serum were associated with composition of stone formation 2,24,26 our study showed no statistically significant associations.…”

Section: Discussioncontrasting

confidence: 53%

Associations between BMI, serum uric acid, serum glucose, and blood pressure with urinary tract stone opacity

2015

View full text Add to dashboard Cite

Background: Urolithiasis refers to formation of stone in the kidney, ureter, or bladder. Several studies showed metabolic abnormalities were common in urolithiasis patients. The aim of this study was to describe the association between body-mass-index (BMI), serum uric acid, serum glucose, and blood pressure toward stone opacity in urinary tract stone patients.Methods: This study was done retrospectively by reviewing registry data of urinary tract stone patients that had undergone ESWL on January 2008 – December 2013 in Department of Urology Cipto Mangunkusumo Hospital. Data concerning body mass index, serum uric acid, serum glucose, blood pressure, and urinary tract stone opacity were recorded. Associations between body mass index, serum uric acid, serum glucose and blood pressure with urinary tract stone opacity were analyzed using chi-square test.Results: There were 2,889 patients who underwent ESWL on January 2008 – December 2013. We analyzed 242 subjects with complete data. Mean age was ± 12.78 (48.02 years). Male-to-female ratio was 2.27:1. Mean BMI was ± 3.78 (29.91 kg/m2). High risk BMIs were found in 161 patients (66.52%). The proportion of radioopaque stone was 77.69% (188 patients). Twenty two patients (9.1%) had normal blood pressure. Patients with high serum uric acid were 34.30% (83 patients). We found a significant association between random serum glucose level and stone opacity (p < 0.05).Conclusion: There is an association between random serum glucose level and stone opacity in urolithiasis patients. Hyperglycemia patients tend to have radiolucent stone, whereas normoglycemia patients tend to have radioopaque stone.

show abstract

Section: Discussioncontrasting

confidence: 53%

Associations between BMI, serum uric acid, serum glucose, and blood pressure with urinary tract stone opacity

2015

View full text Add to dashboard Cite

show abstract

“…Increased SUA has been shown to predict the risk of hypertension, diabetes mellitus, and cardiovascular disease. [1][2][3] More recent data also point to SUA as a risk marker for progression of chronic kidney disease. 4,5 These observations raise the question as to whether interventions that lower uric acid could confer cardiovascular or renal protection.…”

mentioning

confidence: 99%

Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment

et al. 2011

View full text Add to dashboard Cite

Abstract-Emerging data show that increased serum uric acid (SUA) concentration is an independent risk factor for end-stage renal disease. Treatment with the antihypertensive drug losartan lowers SUA. Whether reductions in SUA during losartan therapy are associated with renoprotection is unclear. We therefore tested this hypothesis. In a post hoc analysis of 1342 patients with type 2 diabetes mellitus and nephropathy participating in the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial, we determined the relationship between month 6 change in SUA and renal endpoints, defined as a doubling of serum creatinine or end-stage renal disease. Baseline SUA was 6.7 mg/dL in placebo and losartan-treated subjects. During the first 6 months, losartan lowered SUA by Ϫ0.16 mg/dL (95% CI: Ϫ0.30 to Ϫ0.01; Pϭ0.031) as compared with placebo. The risk of renal events was decreased by 6% (95% CI: 10% to 3%) per 0.5-mg/dL decrement in SUA during the first 6 months. This effect was independent of other risk markers, including estimate glomerular filtration rate and albuminuria. Adjustment of the overall treatment effects for SUA attenuated losartan's renoprotective effect from 22% (95% CI: 6% to 35%) to 17% (95% CI: 1% to 31%), suggesting that approximately one fifth of losartan's renoprotective effect could be attributed to its effect on SUA. Losartan lowers SUA levels compared with placebo treatment in patients with type 2 diabetes mellitus and nephropathy. The degree of reduction in SUA is subsequently associated with the degree in long-term renal risk reduction and explains part of losartan's renoprotective effect. These findings support the view that SUA may be a modifiable risk factor for renal disease. (Hypertension. 2011;58:2-7.)Key Words: serum uric acid Ⅲ angiotensin receptor blocker Ⅲ losartan Ⅲ diabetic nephropathy Ⅲ type 2 diabetes mellitus O ver the past decades, serum uric acid (SUA) has emerged as a cardiovascular risk marker. Increased SUA has been shown to predict the risk of hypertension, diabetes mellitus, and cardiovascular disease. [1][2][3] More recent data also point to SUA as a risk marker for progression of chronic kidney disease. 4,5 These observations raise the question as to whether interventions that lower uric acid could confer cardiovascular or renal protection. In this respect, the angiotensin receptor blocker losartan is of potential interest. The drug has been clearly demonstrated to be renoprotective in patients with diabetic nephropathy, with this effect largely attributed to its effects on blood pressure and/or proteinuria/albuminuria. 6 However, it is unclear whether other off-target effects of the drug could contribute to the ultimate improvement in renal outcome with this agent. Importantly, previous studies have shown that losartan lowers SUA. This hypouricemic effect does not occur with other angiotensin receptor blockers 7 and appears to be largely mediated through reductions in the level of human urate transporter 1 (URAT1) ...

show abstract

“…Very recently, several well-designed prospective studies [79][80][81] provided stronger evidence concerning the relationship between high serum uric acid level and the risk of type 2 diabetes. All these prospective studies adjusted for metabolic syndrome components to validate an independent association between uric acid and diabetes, which was not sufficiently demonstrated previously.…”

Section: Uric Acid and Type 2 Diabetesmentioning

confidence: 99%

Ürik Asidin Antioksidan ve Pro-Oksidan Özellikleri ile İlgili Kavram ve Tartışmalarının Derlemesi

Kumar¹,

Aruna²,

Naidu³

et al. 2015

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Uric acid, the end product of purine catabolism in humans and is known for its crystal deposition at higher concentrations (>7 mg/dl) in gout. Less is known about its antioxidant property and the beneficial effects in various diseases. It is thought that high concentration of uric acid in humans is an evolutionary advantage and it is also hypothesized that high concentration of uric acid is to compensate the antioxidant capacity of ascorbic acid which is lost in humans during the course of evolution. In the extracelluar environment, uric acid can scavenge free radicals like hydroxyl radical, singlet oxygen and peroxynitrite radical therefore, it is considered as a powerful antioxidant. On the other hand uric acid depending upon the chemical milieu, changing its property and at times it acts as pro oxidant and is associated with the pathobiochemistry in developing various diseases like hypertension, cardio vascular diseases, ischemia reperfusion injury, diabetes mellitus, non alcoholic fatty liver disorders etc. In this review, we tried to summarize the evolutionary advantages of hyperuricaemia, effects of both antioxidant property and pro-oxidant nature of uric acid in various disease conditions.

show abstract

Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study

Cited by 257 publications

References 28 publications

Associations between BMI, serum uric acid, serum glucose, and blood pressure with urinary tract stone opacity

Associations between BMI, serum uric acid, serum glucose, and blood pressure with urinary tract stone opacity

Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment

Ürik Asidin Antioksidan ve Pro-Oksidan Özellikleri ile İlgili Kavram ve Tartışmalarının Derlemesi

Contact Info

Product

Resources

About